Pediatric HIV infection: the state of antiretroviral therapy (Q37124873)

18 August 2017

1 reference

title

Pediatric HIV infection: the state of antiretroviral therapy (English)

1 reference

18 August 2017

main subject

anti-retroviral agent

0 references

3

Robert Colebunders

1 reference

18 August 2017

Mehri S McKellar

1

1 reference

18 August 2017

Steven F J Callens

series ordinal

2

1 reference

18 August 2017

publication date

1 April 2008

1 reference

Expert Review of Anti-infective Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

167-180

1 reference

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Pediatric HIV infection: diagnostic laboratory methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

HIV-1 ICD p24 antigen detection in ugandan infants: use in early diagnosis of infection and as a marker of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Ultrasensitive p24 antigen assay for diagnosis of perinatal human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Potential of a simplified p24 assay for early diagnosis of infant human immunodeficiency virus type 1 infection in Haiti

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Adaptation of the ultrasensitive HIV-1 p24 antigen assay to dried blood spot testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Evaluation of dried whole blood spots obtained by heel or finger stick as an alternative to venous blood for diagnosis of human immunodeficiency virus type 1 infection in vertically exposed infants in the routine diagnostic laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. New York City Perinatal HIV Transmission Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Viral counts count in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Acute HIV infection among Kenyan infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Lipodystrophy syndrome in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

A trial of three antiretroviral regimens in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Developmental pharmacology--drug disposition, action, and therapy in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Nevirapine use in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Lopinavir/ritonavir: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.2.167

21 January 2018

Identifiers

DOI

10.1586/14787210.6.2.167

1 reference

18 August 2017

1 reference